Skip to content

Clinical trials

Inflammatory Bowel Diseases trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Inflammatory Bowel Diseases Country / region: Canada Clear all

155 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20032
20041
20053
20064
20073
20081
20095
20105
20115
20126
20139
20146
20156
20168
20179
201811
20195
20208
202112
20228
20235
202413
20258
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed71
Recruiting28
Terminated19
Active, not recruiting15
Unknown status14
Withdrawn4
Not yet recruiting3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Alberta11
University of British Columbia11
Mount Sinai Hospital, Canada8
Eli Lilly and Company7
McMaster University6
Janssen Research & Development, LLC5
Children's Hospital of Eastern Ontario4
McGill University Health Centre/Research Institute of the McGill University Health Centre4
McMaster Children's Hospital4
Pfizer4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Inflammatory Bowel Diseases155
Crohn Disease79
Colitis, Ulcerative73
Colitis12
Gastrointestinal Diseases8
Colonic Neoplasms6
Colorectal Neoplasms6
Intestinal Diseases6
Diverticulitis5
Colonic Diseases4

Trials

Showing 26 to 50 of 155. Each trial links to its page on Pharma Observatory.

55 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.